BeyondSpring - BYSI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.98
▼ -0.45 (-13.12%)

This chart shows the closing price for BYSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BeyondSpring Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BYSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BYSI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BeyondSpring in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.98.

This chart shows the closing price for BYSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in BeyondSpring. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2023Robert W. BairdLower Target$4.00 ➝ $1.25Low
3/15/2023Robert W. BairdLower Target$11.00 ➝ $4.00Low
12/2/2021Evercore ISILower TargetOutperform$95.00 ➝ $25.00High
12/2/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$38.00 ➝ $5.00Medium
12/1/2021Bank of AmericaDowngradeBuy ➝ Underperform$45.00 ➝ $5.00High
12/1/2021William BlairDowngradeOutperform ➝ Market PerformN/A
12/1/2021HC WainwrightDowngradeBuy ➝ NeutralN/A
9/20/2021HC WainwrightLower TargetBuy$100.00 ➝ $65.00High
9/10/2021HC WainwrightReiterated RatingBuy$100.00High
9/8/2021Robert W. BairdInitiated CoverageOutperform$50.00Low
8/27/2021William BlairReiterated RatingBuyLow
8/19/2021Evercore ISIReiterated RatingBuyMedium
8/4/2021Evercore ISIBoost TargetPositive ➝ Outperform$30.00 ➝ $95.00High
8/4/2021HC WainwrightUpgradeNeutral ➝ Buy$100.00N/A
6/28/2021HC WainwrightReiterated RatingHoldHigh
4/5/2021HC WainwrightDowngradeBuy ➝ NeutralLow
1/11/2021Bank of AmericaInitiated CoverageBuy$25.00High
12/28/2020Evercore ISIInitiated CoverageOutperform$30.00N/A
11/24/2020HC WainwrightLower TargetBuy$46.00 ➝ $43.00Low
6/15/2020HC WainwrightReiterated RatingBuy$30.00 ➝ $46.00High
6/9/2020HC WainwrightReiterated RatingBuy$30.00Low
4/29/2020HC WainwrightReiterated RatingBuy$30.00Low
3/30/2020HC WainwrightLower TargetBuy$41.00 ➝ $30.00Low
3/19/2020William BlairReiterated RatingBuyHigh
2/7/2020Jefferies Financial GroupInitiated CoverageBuy$25.00Low
1/10/2020William BlairReiterated RatingBuyHigh
1/10/2020Nomura SecuritiesInitiated CoverageBuy$34.00High
12/3/2019William BlairInitiated CoverageOutperformLow
9/18/2019HC WainwrightReiterated RatingBuy$41.00Medium
7/10/2019HC WainwrightReiterated RatingBuy$60.00Low
(Data available from 5/28/2019 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/29/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/28/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BeyondSpring logo
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $2.98
Low: $2.97
High: $3.63

50 Day Range

MA: $2.62
Low: $1.76
High: $3.63

52 Week Range

Now: $2.98
Low: $0.65
High: $4.00

Volume

88,400 shs

Average Volume

156,558 shs

Market Capitalization

$116.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of BeyondSpring?

The following sell-side analysts have issued research reports on BeyondSpring in the last twelve months:
View the latest analyst ratings for BYSI.

What is the current price target for BeyondSpring?

0 Wall Street analysts have set twelve-month price targets for BeyondSpring in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BeyondSpring in the next year.
View the latest price targets for BYSI.

What is the current consensus analyst rating for BeyondSpring?

BeyondSpring currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BYSI.

What other companies compete with BeyondSpring?

How do I contact BeyondSpring's investor relations team?

BeyondSpring's physical mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company's listed phone number is (646) 305-6387 and its investor relations email address is [email protected]. The official website for BeyondSpring is www.beyondspringpharma.com. Learn More about contacing BeyondSpring investor relations.